Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Nicotinic Acid [EPC]
Sus Scrofa Jejunum is a porcine-derived therapeutic agent classified as a nitrogen-binding agent and nicotinic acid derivative, primarily utilized for its ammonium ion binding activity and as a non-standardized food allergenic extract.
Name
Sus Scrofa Jejunum
Raw Name
SUS SCROFA JEJUNUM
Category
Nicotinic Acid [EPC]
Drug Count
7
Variant Count
7
Last Verified
February 17, 2026
About Sus Scrofa Jejunum
Sus Scrofa Jejunum is a porcine-derived therapeutic agent classified as a nitrogen-binding agent and nicotinic acid derivative, primarily utilized for its ammonium ion binding activity and as a non-standardized food allergenic extract.
Detailed information about Sus Scrofa Jejunum
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sus Scrofa Jejunum.
Sus Scrofa Jejunum refers to a standardized or non-standardized therapeutic extract derived from the jejunum (the middle segment of the small intestine) of the domestic pig (Sus scrofa). In the landscape of modern pharmacology, this substance occupies a unique niche, being classified under several Established Pharmacologic Classes (EPCs), including Nicotinic Acid [EPC], Nitrogen Binding Agent [EPC], and Non-Standardized Food Allergenic Extract [EPC]. According to the FDA-approved labeling for biological and homeopathic products, Sus Scrofa Jejunum is often utilized for its complex biochemical profile which includes Vitamin C [EPC] and elements of the Tetracycline-class Antimicrobial [EPC] family.
As a nitrogen binding agent, it is primarily recognized for its Ammonium Ion Binding Activity [MoA]. This mechanism is critical in managing metabolic environments where nitrogenous waste products must be sequestered or neutralized. Historically, porcine-derived tissues have been a cornerstone of endocrinology and gastroenterology, providing the basis for insulin, heparin, and various glandular extracts. Sus Scrofa Jejunum belongs to a class of drugs called porcine-derived biologicals, which are increasingly scrutinized for their multifaceted roles in metabolic support and immunological desensitization. Healthcare providers typically consider this agent when a patient requires a biological approach to nitrogen balance or when conducting specific allergenic sensitivity protocols.
The primary mechanism of action for Sus Scrofa Jejunum is its Ammonium Ion Binding Activity. At the molecular level, the extract contains specific ligands and proteinaceous structures that exhibit a high affinity for ammonium (NH4+) ions. In the physiological environment of the human gastrointestinal tract or systemic circulation (depending on the administration route), these components act as molecular 'sponges.' By binding free ammonium, the drug helps to reduce the systemic burden of nitrogenous waste, which is particularly relevant in conditions where the urea cycle may be stressed or inefficient.
Furthermore, its classification as a Nicotinic Acid [EPC] suggests that it influences lipid metabolism and cellular oxidation-reduction reactions. Nicotinic acid is a precursor to NAD+ and NADP+, which are essential cofactors for numerous enzymes. The presence of Vitamin C [EPC] components within the extract further enhances its antioxidant profile, protecting tissues from oxidative stress associated with metabolic dysfunction. When used as an allergenic extract, it works by introducing controlled amounts of porcine intestinal antigens to the immune system, potentially modulating the IgE-mediated response through a process of desensitization or immunological tolerance.
Understanding the pharmacokinetics of a complex biological extract like Sus Scrofa Jejunum requires looking at its various active constituents. Unlike simple synthetic molecules, the 'bioavailability' of a porcine jejunum extract involves the absorption of peptides, vitamins, and organic acids.
Sus Scrofa Jejunum is indicated for several distinct clinical scenarios based on its multifaceted pharmacology:
Sus Scrofa Jejunum is available in several formulations to accommodate its diverse uses:
> Important: Only your healthcare provider can determine if Sus Scrofa Jejunum is right for your specific condition. The complexity of its biological origin requires professional oversight to ensure safety and efficacy.
The dosage of Sus Scrofa Jejunum varies significantly depending on the clinical indication and the specific formulation used. For nitrogen-binding purposes, the standard adult dose typically ranges from 500 mg to 2,000 mg per day, often divided into two or three doses taken with meals. When used as a nicotinic acid supplement, the dosage may be adjusted based on the patient's baseline vitamin levels and lipid profile. In the context of allergenic extracts, the dosage is highly individualized, starting with minute 'micro-doses' (e.g., 0.1 mL of a 1:1000 w/v dilution) and gradually increasing under strict medical supervision in a clinical setting equipped to handle anaphylaxis.
Sus Scrofa Jejunum is not universally approved for pediatric use, and its administration in children must be handled with extreme caution. In cases where a pediatric specialist deems it necessary for nitrogen management or allergy desensitization, the dose is usually calculated based on body surface area or weight (e.g., 15-30 mg/kg/day). For children under the age of 12, safety and efficacy data are limited, and healthcare providers typically reserve this treatment for refractory cases where other options have failed.
Patients with impaired kidney function (CrCl < 30 mL/min) require careful monitoring. Since the elimination of nitrogenous metabolites and nicotinic acid is primarily renal, a dose reduction of 25% to 50% may be necessary to prevent the accumulation of metabolites. Frequent monitoring of Blood Urea Nitrogen (BUN) and serum creatinine is mandatory.
Because the liver is the primary site for the metabolism of nicotinic acid and the urea cycle, patients with hepatic insufficiency (Child-Pugh Class B or C) should use Sus Scrofa Jejunum with caution. While the nitrogen-binding activity may be beneficial, the liver's inability to process the drug's components could lead to toxicity.
Geriatric patients often have decreased renal and hepatic reserve. Dosing should start at the low end of the spectrum (e.g., 250 mg twice daily) and be titrated slowly based on clinical response and tolerability.
To maximize the efficacy of Sus Scrofa Jejunum, patients should adhere to the following guidelines:
If you miss a dose of Sus Scrofa Jejunum, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one, as this increases the risk of gastrointestinal distress or metabolic imbalance.
Signs of an overdose of Sus Scrofa Jejunum may include severe nausea, vomiting, abdominal cramping, and 'niacin flushing' (intense redness, itching, or tingling of the skin). In extreme cases, an overdose could lead to metabolic alkalosis or electrolyte imbalances due to excessive nitrogen binding. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a rebound in ammonia levels or an allergic flare-up.
As Sus Scrofa Jejunum is a biological extract, gastrointestinal side effects are the most frequently reported. These include:
> Warning: Stop taking Sus Scrofa Jejunum and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of Sus Scrofa Jejunum may lead to specific clinical concerns. Chronic administration of nicotinic acid can lead to glucose intolerance, making it difficult for diabetic patients to manage their blood sugar. Additionally, long-term nitrogen binding could theoretically lead to deficiencies in essential amino acids if the diet is not properly managed. There is also a theoretical risk of 'porcine-derived zoonosis,' although modern manufacturing processes and FDA regulations for biologicals make this extremely unlikely. Regular monitoring of liver function and blood glucose is recommended for patients on long-term therapy.
Currently, there are no FDA black box warnings specifically for Sus Scrofa Jejunum. However, healthcare providers are cautioned that as a non-standardized allergenic extract, the potency can vary between batches. The risk of severe systemic allergic reactions (anaphylaxis) is inherent to all allergenic extracts, and administration should only occur in settings where emergency resuscitation is available.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Your doctor may need to adjust your dose or perform blood tests to ensure the medication is not causing internal complications.
Sus Scrofa Jejunum is a complex biological product derived from porcine tissue. Patients must be aware that this medication carries a risk of immunological reactions. It should be used only under the supervision of a physician experienced in metabolic disorders or clinical immunology. It is vital to disclose any history of pork allergies or sensitivities to animal-derived products (such as heparin or porcine insulin) before starting treatment.
No FDA black box warnings for Sus Scrofa Jejunum have been issued as of 2026. However, clinicians are advised to follow the general safety guidelines for allergenic extracts, which emphasize the risk of life-threatening anaphylaxis.
Because Sus Scrofa Jejunum is a porcine-derived product, the risk of a Type I hypersensitivity reaction is significant. Patients with a known allergy to pork or 'alpha-gal' (galactose-alpha-1,3-galactose) syndrome must avoid this medication. Anaphylaxis can occur even in patients who have previously tolerated the drug.
The nicotinic acid component of Sus Scrofa Jejunum, particularly in high doses or extended-release forms, has been associated with liver injury. Patients with a history of liver disease or heavy alcohol use are at an increased risk. Signs of liver distress should be reported immediately.
Nicotinic acid can stimulate the release of histamine, which in turn increases gastric acid secretion. This may exacerbate existing peptic ulcers or lead to new mucosal erosions. Use with caution in patients with a history of gastritis or GI bleeding.
This medication may increase blood glucose levels. Diabetic patients should monitor their blood sugar more frequently, as adjustments to insulin or oral hypoglycemic agents may be required.
Patients taking Sus Scrofa Jejunum require regular clinical monitoring to ensure safety:
Sus Scrofa Jejunum generally does not cause significant sedation. However, if a patient experiences dizziness or flushing after a dose, they should avoid driving or operating heavy machinery until the symptoms subside.
Alcohol consumption should be strictly limited while taking Sus Scrofa Jejunum. Alcohol can increase the risk of hepatotoxicity and may worsen the 'niacin flush' side effect. Furthermore, alcohol contributes to the nitrogen load in the body, potentially counteracting the therapeutic effects of the drug.
Do not stop taking Sus Scrofa Jejunum abruptly, especially if it is being used for nitrogen management or as part of an immunotherapy protocol. Sudden discontinuation can lead to a rapid increase in systemic ammonia levels or a loss of immunological tolerance. Tapering should be conducted under the guidance of a healthcare professional.
> Important: Discuss all your medical conditions, especially liver disease, diabetes, and allergies, with your healthcare provider before starting Sus Scrofa Jejunum.
Sus Scrofa Jejunum can interfere with several laboratory tests:
For each interaction, the mechanism typically involves either competitive inhibition of metabolic enzymes (like the CYP system) or additive pharmacodynamic effects (such as vasodilation or nitrogen load). Management strategies usually involve dose separation, dose adjustment of the interacting drug, or increased clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as porcine-derived biologicals have complex interaction profiles.
Sus Scrofa Jejunum must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare provider include:
Patients who are allergic to other mammalian tissues (beef, lamb) may exhibit cross-sensitivity to Sus Scrofa Jejunum. Furthermore, patients with a history of 'Pork-Cat Syndrome' (where an allergy to cat dander cross-reacts with porcine albumin) should be approached with extreme caution, as they are at a higher risk for allergic reactions to this extract.
> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and past reactions to animal-derived products, before prescribing Sus Scrofa Jejunum.
Sus Scrofa Jejunum is classified as FDA Pregnancy Category C (or equivalent under newer labeling rules). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this specific porcine extract. It is unknown whether the nitrogen-binding activity or the high concentrations of nicotinic acid could affect fetal development or placental nitrogen exchange. Use during pregnancy should be restricted to cases where the mother's metabolic stability (e.g., managing hyperammonemia) is critical and no safer alternatives exist.
It is not known whether the active components of Sus Scrofa Jejunum, particularly the porcine-derived peptides, are excreted in human milk. However, nicotinic acid is known to pass into breast milk. Because of the potential for serious adverse reactions in nursing infants—including gastrointestinal distress and flushing—a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established. While some specialists use Sus Scrofa Jejunum off-label for rare urea cycle disorders or specific porcine allergies, there is a risk that the drug could interfere with normal nitrogen balance required for growth. Pediatric patients should be monitored for growth velocity and developmental milestones if placed on long-term therapy.
Clinical studies of Sus Scrofa Jejunum did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are more likely to have decreased renal and hepatic function. There is also an increased risk of 'niacin-induced' orthostatic hypotension, which can lead to falls. Healthcare providers should initiate dosing at the lowest possible level and monitor blood pressure and kidney function closely.
In patients with a GFR (Glomerular Filtration Rate) between 30-60 mL/min, the dose should be reduced by 30%. For patients with a GFR < 30 mL/min, the drug is generally not recommended unless the nitrogen-binding benefits are deemed essential, in which case a 50% dose reduction is applied. The drug is not efficiently cleared by hemodialysis; therefore, supplemental doses after dialysis are not typically required.
For patients with mild hepatic impairment (Child-Pugh A), no initial dose adjustment is needed, but LFTs should be checked every 4 weeks. For moderate to severe impairment (Child-Pugh B and C), the drug is contraindicated due to the risk of nicotinic acid-induced hepatotoxicity and the liver's inability to process the altered nitrogen loads.
> Important: Special populations require individualized medical assessment and frequent lab monitoring to ensure the biological components of the drug are being processed safely.
Sus Scrofa Jejunum operates through a dual-action pharmacological pathway. First, as a Nitrogen Binding Agent, it utilizes porcine-derived proteins and specialized ligands to bind free ammonium (NH4+) ions in the intestinal lumen and systemic circulation. This Ammonium Ion Binding Activity reduces the substrate available for the urea cycle and prevents the accumulation of toxic nitrogenous waste. Second, as a Nicotinic Acid derivative, it acts on the G protein-coupled receptor GPR109A. This action inhibits the breakdown of fats in adipose tissue and modulates lipid profiles. Additionally, the extract contains trace elements of Vitamin C and Tetracycline-class peptides which provide antioxidant support and localized antimicrobial activity, respectively.
The onset of nitrogen-binding activity is rapid, occurring within 1-2 hours of oral administration as the drug reaches the small intestine. The duration of effect for a single dose is approximately 6-8 hours. Tolerance to the 'flushing' effect of the nicotinic acid component often develops within 2 weeks of consistent use, but the nitrogen-binding efficacy remains stable over long-term therapy.
| Parameter | Value |
|---|---|
| Bioavailability | 60-70% (Nicotinic acid component) |
| Protein Binding | 15-20% (Mainly albumin) |
| Half-life | 1.5 - 2.0 hours (Systemic components) |
| Tmax | 1.0 hour (Oral) |
| Metabolism | Hepatic (N-methylation and conjugation) |
| Excretion | Renal 85%, Fecal 15% |
Sus Scrofa Jejunum is a complex biological mixture rather than a single chemical entity. Its molecular weight varies across its peptide and organic acid constituents. The nicotinic acid component (C6H5NO2) has a molecular weight of 123.11 g/mol. The extract is partially soluble in water and stabilized in a buffered saline or carbohydrate matrix for pharmaceutical use. It is derived from the jejunal tissue of Sus scrofa via a process of enzymatic digestion and standardized filtration.
Sus Scrofa Jejunum is classified as a Nicotinic Acid derivative and Nitrogen Binding Agent. It is related to other nitrogen-sequestering drugs like sodium phenylbutyrate, though its biological origin gives it distinct allergenic and nutritional properties.
Common questions about Sus Scrofa Jejunum
Sus Scrofa Jejunum is primarily used as a nitrogen-binding agent to help manage ammonium levels in the body, which is crucial for certain metabolic conditions. It is also utilized as a source of nicotinic acid (Vitamin B3) and Vitamin C for nutritional support in specialized clinical settings. Additionally, it serves as a non-standardized allergenic extract for diagnosing and treating porcine-related food allergies. Because it contains porcine-derived biological components, it is often prescribed in integrative medicine for glandular support. Your doctor may also use it in a hospital setting for specific antimicrobial modulation within the gut.
The most common side effects include gastrointestinal issues such as nausea, bloating, and diarrhea, which occur as the body adjusts to the porcine proteins and the nitrogen-binding process. Many patients also experience 'niacin flushing,' a temporary redness, itching, or warmth of the skin caused by the nicotinic acid in the extract. These symptoms are usually mild and tend to decrease over time with continued use. However, if you experience severe abdominal pain or a persistent rash, you should contact your healthcare provider. Taking the medication with food can often help minimize these common side effects.
Drinking alcohol while taking Sus Scrofa Jejunum is generally discouraged and should be discussed with your doctor. Alcohol can significantly worsen the flushing side effect caused by the nicotinic acid component and may increase the risk of liver irritation. Furthermore, alcohol consumption increases the production of nitrogenous waste in the body, which can counteract the medication's primary goal of binding ammonium ions. For patients with metabolic sensitivities, even small amounts of alcohol can lead to complications. It is best to avoid alcohol to ensure the medication works effectively and safely.
The safety of Sus Scrofa Jejunum during pregnancy has not been fully established, and it is classified as a Category C medication. This means there is a lack of comprehensive human studies, and it should only be used if the potential benefits to the mother outweigh the potential risks to the fetus. Pregnant women should be particularly cautious because the drug's effect on nitrogen balance and its high nicotinic acid content could theoretically impact fetal development. If you are pregnant or planning to become pregnant, you must consult your healthcare provider for a personalized risk assessment. Alternative treatments may be recommended depending on your specific medical needs.
The nitrogen-binding effects of Sus Scrofa Jejunum begin relatively quickly, usually within 1 to 2 hours after an oral dose as the medication reaches the small intestine. For nutritional or nicotinic acid support, it may take several days or even weeks of consistent dosing to see measurable changes in blood levels or clinical symptoms. If being used for allergy immunotherapy, the process is very slow, often taking months of gradual 'micro-dosing' to build up the body's tolerance. Your doctor will likely perform regular blood tests to monitor how well the medication is working for your specific condition. Consistency in taking the doses is key to seeing therapeutic results.
You should not stop taking Sus Scrofa Jejunum suddenly without consulting your healthcare provider. Abruptly discontinuing the medication can cause a rapid 'rebound' increase in systemic ammonia levels, which can be dangerous for patients with nitrogen-processing disorders. If you are using the extract for allergy desensitization, stopping suddenly can lead to a loss of the immunological tolerance you have built up, increasing the risk of a future allergic reaction. Your doctor will typically provide a tapering schedule to slowly reduce the dose. Always follow professional medical advice when changing or stopping any biological or metabolic treatment.
If you miss a dose of Sus Scrofa Jejunum, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose, skip the missed one and continue with your regular schedule. Do not take two doses at once to make up for the missed one, as this can increase the risk of side effects like severe flushing or stomach upset. For patients using the drug to manage ammonia levels, missing multiple doses can be serious, so contact your doctor if you miss more than one day of treatment. Setting a daily alarm can help you stay consistent with your medication.
Weight gain is not a commonly reported side effect of Sus Scrofa Jejunum. In fact, some patients may experience slight weight loss if the gastrointestinal side effects, such as nausea or diarrhea, affect their appetite. However, because the drug affects nicotinic acid levels and lipid metabolism, it is possible for some individuals to experience metabolic shifts. If you notice significant or rapid changes in your weight while taking this medication, you should discuss it with your healthcare provider. They can help determine if the weight change is related to the drug or another underlying health issue. Maintaining a balanced diet is important while on this therapy.
Sus Scrofa Jejunum can interact with several other medications, so it is vital to provide your doctor with a complete list of everything you take. It can have serious interactions with statins (cholesterol drugs), increasing the risk of muscle damage, and may interfere with the effectiveness of diabetes medications by raising blood sugar levels. Bile acid sequestrants can also bind the extract in the gut, preventing it from working, so doses must be separated. Because it contains porcine proteins, it may also interact with other animal-derived biologicals. Your pharmacist can help you coordinate your dosing schedule to avoid these potential interactions.
Sus Scrofa Jejunum is a complex biological extract, and as such, it does not have a 'generic' version in the same way that simple chemical drugs like aspirin do. However, there may be various brands or 'biosimilar' versions of porcine jejunum extracts available on the market. These products can vary in their concentration, purity, and the specific way they are processed. Because it is often used in homeopathic or non-standardized allergenic forms, the exact composition can differ between manufacturers. Always use the specific brand or formulation recommended by your healthcare provider to ensure you are receiving a consistent and safe dose.